Mostrar el registro sencillo del ítem
dc.contributor.author
Pontiggia, Osvaldo Alejandro
dc.contributor.author
Fiszman, Gabriel Leon
dc.contributor.author
Rodriguez, Vanina
dc.contributor.author
Bal, Elisa Dora
dc.contributor.author
Simian, Marina
dc.date.available
2019-09-09T17:51:07Z
dc.date.issued
2007-12
dc.identifier.citation
Pontiggia, Osvaldo Alejandro; Fiszman, Gabriel Leon; Rodriguez, Vanina; Bal, Elisa Dora; Simian, Marina; Stromal-epithelial interactions and tamoxifen resistance; Medicina (Buenos Aires); Medicina (Buenos Aires); 67; Supp. II; 12-2007; 60-64
dc.identifier.issn
0025-7680
dc.identifier.uri
http://hdl.handle.net/11336/83123
dc.description.abstract
Tamoxifen, a selective estrogen receptor modulator, is the standard endocrine treatment for hormone receptor positive breast cancer, both in the initial adjuvant therapy and as treatment of patients with metastatic disease. However, about one third of patients with estrogen receptor (ER)-á positive tumors are refractory to tamoxifen therapy and a high percentage of patients who initially respond to tamoxifen develop resistance. Most breast cancers that acquire endocrine resistance retain ER-á expression, suggesting that loss of ER is not a common mechanism of resistance to endocrine therapy. Diverse signal transduction pathways influence the functional activity of ER, in addition to steroid ligand, and are critical in the responsiveness of tumors to anti-hormonal drugs. In particular, it is now well established that activation of several growth factor signaling cascades can promote resistance. However, although these pathways can be modulated by the tumor microenvironment, no studies to our knowledge have investigated this subject in an ER-á positive cell context. In this article we discuss the development of a new mouse model of estrogen responsive/tamoxifen sensitive breast cancer and propose that microenvironmental factors may be critical in the response to endocrine therapy, and could in the future be a rational target for the treatment of tamoxifen resistant breast cancer.á positive tumors are refractory to tamoxifen therapy and a high percentage of patients who initially respond to tamoxifen develop resistance. Most breast cancers that acquire endocrine resistance retain ER-á expression, suggesting that loss of ER is not a common mechanism of resistance to endocrine therapy. Diverse signal transduction pathways influence the functional activity of ER, in addition to steroid ligand, and are critical in the responsiveness of tumors to anti-hormonal drugs. In particular, it is now well established that activation of several growth factor signaling cascades can promote resistance. However, although these pathways can be modulated by the tumor microenvironment, no studies to our knowledge have investigated this subject in an ER-á positive cell context. In this article we discuss the development of a new mouse model of estrogen responsive/tamoxifen sensitive breast cancer and propose that microenvironmental factors may be critical in the response to endocrine therapy, and could in the future be a rational target for the treatment of tamoxifen resistant breast cancer.á expression, suggesting that loss of ER is not a common mechanism of resistance to endocrine therapy. Diverse signal transduction pathways influence the functional activity of ER, in addition to steroid ligand, and are critical in the responsiveness of tumors to anti-hormonal drugs. In particular, it is now well established that activation of several growth factor signaling cascades can promote resistance. However, although these pathways can be modulated by the tumor microenvironment, no studies to our knowledge have investigated this subject in an ER-á positive cell context. In this article we discuss the development of a new mouse model of estrogen responsive/tamoxifen sensitive breast cancer and propose that microenvironmental factors may be critical in the response to endocrine therapy, and could in the future be a rational target for the treatment of tamoxifen resistant breast cancer.á positive cell context. In this article we discuss the development of a new mouse model of estrogen responsive/tamoxifen sensitive breast cancer and propose that microenvironmental factors may be critical in the response to endocrine therapy, and could in the future be a rational target for the treatment of tamoxifen resistant breast cancer.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
Medicina (Buenos Aires)
dc.rights
info:eu-repo/semantics/openAccess
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.subject.classification
Inmunología
dc.subject.classification
Medicina Básica
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD
dc.title
Stromal-epithelial interactions and tamoxifen resistance
dc.title
Interacciones estroma-epitelial al tamoxifeno
dc.type
info:eu-repo/semantics/article
dc.type
info:ar-repo/semantics/artículo
dc.type
info:eu-repo/semantics/publishedVersion
dc.date.updated
2019-05-08T18:27:15Z
dc.identifier.eissn
1669-9106
dc.journal.volume
67
dc.journal.number
Supp. II
dc.journal.pagination
60-64
dc.journal.pais
Argentina
dc.journal.ciudad
Buenos Aires, argentina
dc.description.fil
Fil: Pontiggia, Osvaldo Alejandro. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Oncología "dr.angel Roffo". Departamento de Radioterapia y Cancer Experimental; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
dc.description.fil
Fil: Fiszman, Gabriel Leon. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Oncología "dr.angel Roffo". Departamento de Radioterapia y Cancer Experimental; Argentina
dc.description.fil
Fil: Rodriguez, Vanina. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Oncología "dr.angel Roffo". Departamento de Radioterapia y Cancer Experimental; Argentina
dc.description.fil
Fil: Bal, Elisa Dora. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Oncología "dr.angel Roffo". Departamento de Radioterapia y Cancer Experimental; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
dc.description.fil
Fil: Simian, Marina. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Oncología "dr.angel Roffo". Departamento de Radioterapia y Cancer Experimental; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
dc.journal.title
Medicina (Buenos Aires)
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/http://www.scielo.org.ar/scielo.php?script=sci_serial&pid=0025-7680&lng=es&nrm=iso
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://www.medicinabuenosaires.com/indices-de-2000-a-2009/
Archivos asociados